139th National Cancer Advisory Board
as a training center for the intramural and extramural communities and propagate standardization in the field.
Dr. Libutti closed with an acknowledgement of the members of the TARP steering committee, which represent a number of different institutes, as well as the efforts of Ms. Kathleen Schlom, Office of the Director, NCI.
CLOSED SESSION—DR. CAROLYN D. RUNOWICZ
This portion of the meeting was closed to the public in accordance with the provisions set forth in Sections 552b(c)(4), 552(b(c)(6), Title 5 U.S. code and 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. appendix 2).
Members were instructed to exit the room if they deemed their participation in the deliberation of any matter before the Board to be a real conflict or that it would represent the appearance of a conflict. Members were asked to sign a conflict-of-interest/confidentiality certification to this effect.
The en bloc vote for concurrence with IRG recommendation was affirmed by all serving Board members present. During the closed session of the meeting, a total of 2,164 applications were reviewed requesting support of $ 591,824.139. The subcommittee adjourned at 5:30 p.m.
THURSDAY, SEPTEMBER 7, 2006
NCI CANCER CENTERS DIRECTOR’S REPORT—DRS. JOHN MENDELSOHN AND MARTIN D. ABELOFF
Drs. John Mendelsohn and Martin D. Abeloff presented recommendations from the NCI- designated Cancer Center directors to accelerate successes against cancer. The recommendations resulted from two meetings and a number of teleconferences between the Cancer Center directors and the NCI Director, and were shared in a report that aimed to diminish confusion over goals and expectations regarding the 2015 target, provide a blueprint for achieving what is possible, cope with frustration over the reduction in NCI funding at a time of great opportunity for increased successes, and recognize the advantages of increased collaboration and joint activities. Key points from the report include: (1) NCI- designated Cancer Centers have implemented programs that lead the way in each of the three initiatives of the NIH Roadmap; (2) Cancer Centers, unlike the NCI, have dual missions: research and dissemination of improved care to patients; (3) deaths from cancer can be reduced substantially by broadening the application of current knowledge, and Cancer Centers can lead the way; and (4) the promise of “personalized” medicine is achievable.
The Cancer Center Directors’ Working Group identified four goals: (1) reduce the burden of cancer through research in the areas of prevention, detection, treatment, and survivorship, and create a strategy for success; (2) identify ways in which NCI-designated Cancer Centers can enhance collaboration with each other and with other stakeholders in the pursuit of our shared mission; (3) suggest initiatives that will enable the Cancer Centers to extend their research beyond their local communities and to provide leadership in the wide dissemination of best practices in cancer and prevention; and (4) create a realistic vision of the potential for future successes and identify the roadblocks.
Notable progress has been made. The ACS, for example, has performed a midpoint analysis of the goal of 50 percent reduction in deaths, 1990-2015, and projected the success rate to be 23 percent